ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Agendia Named 2025 “Best Overall Genomics Company” By MedTech Breakthrough
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital Read More
The Endocrine System and Breast Cancer Overview
The endocrine system is a series of glands responsible for creating and distributing hormones throughout the body, chemical messengers of sorts. This important system plays a role in many bodily functions, including regulating metabolism, Read More
Disparities in Breast Cancer Care, Genomic Insights and Early Detection
By Ryan Scott | March 19, 2025 Black women face a 40% higher mortality rate from breast cancer compared with other groups, according to the Breast Cancer Research Foundation, highlighting a disparity in detection, Read More
Breast Cancer Statistics 2024
Authors Angela N. Giaquinto MSPH | Hyuna Sung PhD | Lisa A. Newman MD, MPH | Rachel A. Freedman MD, MPH | Robert A. Smith PhD | Jessica Star MA, MPH | Ahmedin Jemal Read More
News
Media Releases
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® in Diverse Patient Populations Across Breast Cancer Subtypes IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 27, 2025 – Agendia®, Inc., a leader in precision Read More
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
FLEX Study reaches milestone of 20,000 enrolled patients, providing new insights on genomic testing across diverse patient populations IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 15, 2025 – Agendia®, Inc., announced today that Read More
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among MammaPrint® High Risk HR+ HER2- breast cancers, supporting more personalized treatment strategies. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – May 6, 2025 – Agendia®, Inc., Read More
Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting
Poster presentation to highlight new data on MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting. Agendia to present at Breast Fellows University Annual Meeting and host Educational Dinner Symposium Read More